BioSpace News Archive

Summit Therapeutics plc announces that it has demonstrated the potential of its DDS-04 series of new class antibiotics as an Enterobacteriaceae-targeted treatment through in vivo proof of concept data in sepsis and pneumonia animal models.

Issuance of U.S. Patent No. 10,335,391 Further Strengthens Aclaris’ RHOFADE Patent Portfolio

Clearside Biomedical, Inc. announced its entry into a worldwide licensing agreement with Aura Biosciences for the use of Clearside’s Suprachoroidal Space Microinjector™ to deliver Aura’s proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choroidal melanoma.

Immutep Limited, an Australian biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, has announced an equity financing to raise gross proceeds of approximately A$10 million.

CorMedix Inc. announced that it has received feedback from the U.S. FDA regarding the submitted statistical analyses of data and additional information requested by the FDA for the primary and secondary efficacy endpoints of the Company’s LOCK-IT-100 clinical study.

Tennessee’s innovative clinical trials network is soaring just one year into operations, bringing growing benefits for Tennesseans and the advancement of health care across the state.

Biodiscovery company joins MIT accelerator for high-potential startups

NANOBIOTIX announced that the previously reported results from the Phase II/III Act.In.Sarc trial evaluating NBTXR3 in patients with advanced STS have been published online in The Lancet Oncology.

Nephros, Inc., a commercial-stage company that develops and sells high performance water purification products to the medical device and commercial markets, announced preliminary financial results for the quarter ended June 30, 2019.

Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, provided an update on the progress of the development of odevixibat for pediatric cholestatic liver diseases and elobixibat for NASH.